CV Therapeutics gains on FDA approval
Shares of CV Therapeutics, Inc. (Nasdaq:CVTX) are treading higher this morning after the biopharmaceutical company said late Thursday night that the U.S. Food and Drug Administration approved the company’s and Astellas Pharma US’s lexiscan injection for use as a stress agent in radionuclide myocardial perfusion imaging, a test that detects and characterizes coronary artery disease in patients unable to undergo adequate exercise stress.
Shares gained 9%, or $0.72, to $8.75 in pre-market trading. For detailed price information and recent news stories about CV Therapeutics, click CVTX.
